FIA
MRSN

FNY Investment Advisers’s Mersana Therapeutics MRSN Stock Holding History

FNY Investment Advisers’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-44
Closed -$1K – 666
2023
Q3 		$1K Buy
+44
New +$2.09K ﹤0.01% 570
2021
Q1 		– Sell
-6,608
Closed -$4.39M – 932
2020
Q4 		$4.39M Sell
6,608
-1,384
-17% -$770K 1.2% 15
2020
Q3 		$3.72M Buy
7,992
+2,215
+38% +$1.12M 1.57% 12
2020
Q2 		$3.38M Buy
5,777
+3,441
+147% +$1.18M 1.97% 6
2020
Q1 		$340K Buy
+2,336
New +$408K 0.26% 81

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FNY Investment Advisers's MRSN Position: Q4 2023 in Review

FNY Investment Advisers sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 44 shares — an estimated $1K sold.

FNY Investment Advisers first reported a position in MRSN in Q1 2020 and held it in 5 quarters. The position peaked at $4.39M in Q4 2020. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • FNY Investment Advisers reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • FNY Investment Advisers sold 44 Mersana Therapeutics shares in Q4 2023, an estimated $1K.
  • FNY Investment Advisers first reported a position in Mersana Therapeutics in Q1 2020 and held it in 5 quarters.
  • FNY Investment Advisers's Mersana Therapeutics position peaked at $4.39M in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on FNY Investment Advisers's 13F filing for Q4 2023, filed 12 Jan 2024.